PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
- HDP-101 demonstrated complete response in one female patient from cohort 5
- R&D Webinar to be hosted on 17 June 2025
Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting new clinical data on its lead Amanitin-based ADC candidate,
HDP-101 at the 30th European Hematology Association (EHA) Congress, taking place in Milan, Italy, from 12 – 15 June 2025.
The Amanitin-based ADC candidate HDP-101 is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory Multiple Myeloma. HDP-101 is showing encouraging results, including an ongoing complete response in a female patient from cohort 5 who had been heavily pretreated and who has been treated continuously with HDP-101 alone for more than 19 months.
In addition, promising biological activity and objective improvements were observed in several patients, underscoring the potential of HDP-101 as a treatment option for Multiple Myeloma. The study is advancing in cohort 8 at a dose of 140 µg/kg.
EHA 2025 Congress
Poster Presentation Title: The Anti-BCMA Antibody Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase I/IIa clinical trial as it advances into Cohort 7
|
Abstract number: |
PF749 |
|
Session: |
1 |
|
Presentation time: |
13 June, 18:30 – 19:30 CEST |
|
Speaker: |
Dr. Shambavi Richard |
|
Link to abstract: |
EHA Library - The official digital education library of European Hematology Association (EHA) |
R&D Webinar “Pioneering New Treatment Options in Relapsed or Refractory Multiple Myeloma with a New Amanitin-based ADC”
Following the EHA Congress, Heidelberg Pharma will host an R&D webinar on 17 June at 17:00 CEST to provide further insights into the ongoing clinical trial of its lead candidate, HDP-101.
The R&D webinar will include presentations from Heidelberg Pharma’s management team, alongside Key Opinion Leaders (KOLs) in the field of Multiple Myeloma, Jonathan Kaufman, MD, Associate Professor of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, USA and Professor Marc-Steffen Raab, MD, Director Heidelberg Myeloma Center, Heidelberg University Hospital, Heidelberg, Germany.
Attendees are invited to submit questions in advance or participate in a live Q&A session following the presentation.
For further information about the R&D webinar or to register your interest, please contact
https://beacon-intelligence.com/webinars/pioneering-new-treatment-options-in-relapsed-or-refractory-multiple-myeloma-with-a-new-amanitin-based-adc/
A recording of the webinar will be made available shortly after the event in the section “Press & Investors > Conferences & Calendar > Conferences & Presentations” of the Company website shortly after the event.